Albatross Drugs And Biotech Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 3.00 M
- Company Age 21 Year, 9 Months
- Last Filing with ROC 31 Mar 2011
- Open Charges ₹ 3.75 M
About Albatross Drugs And Biotech
Albatross Drugs And Biotech Private Limited (ADABPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 April 2003 and has a history of 21 years and nine months. Its registered office is in Palakkad, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2011. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹3.75 M.
Vinod and Geetha Madhavamenon serve as directors at the Company.
Company Details
-
Location
Palakkad, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232KL2003PTC016078
-
Company No.
016078
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Apr 2003
-
Date of AGM
30 Sep 2011
-
Date of Balance Sheet
31 Mar 2011
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Albatross Drugs And Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod
|
Managing Director | 18-Apr-2006 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Geetha Madhavamenon
|
Additional Director | 02-Mar-2012 | Current |
Financial Performance of Albatross Drugs And Biotech.
Enhance accessibility to Albatross Drugs And Biotech's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Albatross Drugs And Biotech?
Unlock access to Albatross Drugs And Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹3.75 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.38 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2008 | Canara Bank | ₹0.25 M | Open |
| 22 Mar 2004 | Canara Bank | ₹3.50 M | Open |
How Many Employees Work at Albatross Drugs And Biotech?
Unlock and access historical data on people associated with Albatross Drugs And Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Albatross Drugs And Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Albatross Drugs And Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
